Risk Factors of Bacterial Resistance to Antibiotics in Internal Medicine and Hemodialysis Nephrology Services at the Edith Lucie Bongo Ondimba General Hospital

Gandzali-Ngabe Pierre Eric¹, Ngoyi Ontsira Nina², Gakosso Odou Philippe³, Loumingou Richard⁴

¹Nephrology Hemodialysis, Édith Lucie BONGO ONDIMBA General Hospital, Oyo, Congo
²Laboratory, Hospital and University Center of Brazzaville, Brazzaville, Congo
³Laboratory, Édith Lucie BONGO ONDIMBA General Hospital Oyo, Brazzaville, Congo
⁴Nephrology, Brazzaville Hospital and University Center, Brazzaville, Congo

Email: ngabe_eric@yahoo.fr

Abstract

Introduction: Antibiotic resistance is a public health problem. It is due to multi-resistant bacteria (MRB). The objective of this study was to determine bacterial resistance to antibiotics in chronic renal failure at the Edith Lucie BONGO ONDIMBA general hospital (HGETBO). Patients, material and method: This was an analytical cross-sectional study conducted from January 1 to August 31, 2019 at the HGETBO. It concerned all patients admitted to the HGETBO with positive bacteriological samples. After a study of the sensitivity to isolated species, the patients were divided into two (02) groups: those MRB positive (+) and not MRB or negative (−). Epi Info software version 3.5.1 was used for the calculation of the rates and the comparison of the variables. The adjusted odds ratio (ORa) with a 95% confidence interval was used to measure the specific effect of each risk factor such as chronic kidney disease and diabetes, in order to rule out confounding factors. Multivariate analysis by binomial logistic regression was used. Results: There were 375 bacteriological samples from 258 patients, among them 247 patients with 235 positive samples or 63%. The eleven (11) are healthy patients. The median age was 33 with extremes ranging from 16 to 90. The female sex was predominant with a sex ratio of 0.6. The majority of MRB+ cases were found in internal medicine and nephrology with 12 cases (38.7%) and hemodialysis with 4 cases (12.9%). Urinary samples were in the majority with 74.5%. Escherichia coli was predominant in 30.3%. After studying the sensitivity to antibiotics of the 247 species included, 113 were MRB+ and 134 BMR− i.e. a frequency of
45.7%. Methicillin-resistant *Staphylococcus aureus* (MRSA) was predominant (51.3%). Multivariate logistic regression analysis showed that the main risk factor was antibiotic use (OR: 3.2 [1.9 - 5.4]; p-value < 0.01). Chronic renal failure and diabetes were not risk factors for carriage. The other risk factors identified were: hospitalization of more than 7 days (prolonged), *S. aureus* infection and male sex. Conclusion: Probabilistic antibiotic therapy leads to the selection of BMRs. Long hospital stays, male sex, and MRSA are risk factors or determinants of antibiotic resistance, but not chronic kidney disease.

### Keywords

Risk Factors, Bacterial Resistance, Antibiotics, Chronic Renal Failure, General Hospital Edith Lucie BONGO ONDIMBA

### 1. Introduction

Bacterial resistance to antibiotics is the ability of certain bacteria to withstand a higher concentration of antibiotics than can be achieved *in vivo* during medical treatment [1]. Bacteria are said to be multi-resistant (MRB) when they accumulate acquired resistance to more than three families of antibiotics [2]. Antibiotic resistance is a public health problem. Bacterial resistance to antibiotics has increased alarmingly in recent years as newer antibiotics are less and less marketed [3] [4] [5] [6]. It is due to multi-resistant bacteria (MRB). Globally, resistance to C3Gs for *Escherichia coli* was 10.2% in France; 15.6% in Portugal; 16.6% in Croatia and 29.5% in Italy [7] [8]. Resistance to ceftazidime for *P. aeruginosa* was 12.2% in France; 18.6% in Portugal; 19.5% in Croatia and 20.0% in Italy. The frequency of MRSA was 12.9% in France; 15.2% in Portugal; 28.5% in Croatia and 33.9% in Italy.

In Africa Mboyo, F.C. in 2016 in Morocco, reported 15% resistance to *E. coli*; 5.6% for *P. aeruginosa* and 1.3% for *S. aureus* [9]; Deguenovo *et al.* in 2016 in Senegal reported a frequency of 62% for EBLSE and 13% for *P. aeruginosa* [10].

In Congo, Moyen R. *et al.* in 2014 showed that beta-lactam resistance was 77.9% for *S. aureus*; 44.4% for *P. aeruginosa*; and it ranged from 56.3 to 83.3 for Enterobacteriaceae [11]. However, the determinants of this resistance are not known in our region. The objective of this study was; in general to analyze the determinants of bacterial resistance to antibiotics at the Edith Lucie BONGO ONDIMBA general hospital (H格尔BO), and specifically: 1) Determine the frequency of multiresistant bacteria to H格尔BO; 2) Describe in a comparative manner the socio-demographic and clinical characteristics of patients carrying multi-resistant bacteria (MRB+) and those carrying non-multi-resistant bacteria (MRB−) to H格尔BO; 3) Determine bacterial resistance to antibiotics in chronic renal failure to H格尔BO. 4) Identify the bacteria determining multidrug resistance to H格尔BO antibiotics.
2. Patients, Material and Method

This was an analytical cross-sectional study carried out from January 1 to August 31, 2019 at the HGELBO. Our study took place at the Edith Lucie BONGO ONDIMBA General Hospital (HGELBO) which is located in the Cuvette department and more precisely in the Oyo district. It is a public establishment that was put into service on March 10, 2017. It has 200 beds of which 148 are active with a monthly attendance of 255 patients. Our study was performed in the biomedical analysis laboratory. Patient recruitment was done on an outpatient basis, in inpatient departments or directly in the biomedical analysis laboratory. The target population consisted of any patient admitted to the HGELBO regardless of age, sex, origin, existence or not of an infectious pathology and in whom a bacteriological examination of the samples showed a positive culture for one of the following germs: Staphylococcus aureus, Enterobacteriaceae, Pseudomonas aeruginosa, Acinetobacter baumannii. We included patients with:

- gave their informed consent to the study.
- is the subject of the following samples: urine, vaginal secretions, put, puncture of joint fluid, hemodialysis catheter tip, probe tip.
- a positive culture.

Contaminations and epidemiological duplicates were excluded from our study.

The sampling was carried out from a simple random selection.

The sample size was calculated from Schlesselman’s formula to ensure its representativeness. N: sample size; r: MRB+/MRB− ratio that we have arbitrarily chosen 1 MRB+ for 3 MRB− i.e. r = 1/3; P = (P0 + P1)/2 = the average of the proportions; P0 - P1: the difference between the proportions. P0 = Proportion of affected in the subject group (MRB+) and P1 = Proportion of affected in the control group (MRB−). For α = 0.05; Za = 1.65; β being the type I error I = Probability of wrongly saying that there is a difference in the two groups, therefore wrongly rejecting the null hypothesis. For β = 0.1; Zb = 1.28; β being the type II error = Probability of wrongly saying that there is no difference in the two groups, therefore false admission of the null hypothesis. Numerical application: Given the fact that no study was available in Congo to use the variables, we used data from the case-control study carried out in Morocco in 2014 on the risk factors for infections with multidrug-resistant bacteria. At the level of the intensive care units, CHU Ibn Rochd, Casablanca [12] see Table 1. The parameter we considered was the antecedent of diabetes, i.e. 65% of patients presented an infection with ESBL+ E. coli (P0) and 12% had ESBL− (P1) E. coli infection. We have P1 = 0.12; P0 = 0.65; r = 1/3; Za = 1.65; Zb = 1.28. The calculation gives N = 29; hence we have a minimum size of 29 BMR+ and 87 MRB−. It concerned all patients admitted to the HGELBO with positive bacteriological samples. After a study of the sensitivity to the isolated species, the patients were divided into two (02) groups: those MRB positive (+) and not MRB or negative (−). Data collection was centered on a threefold survey: epidemiological, clinical and bacteriological.
Table 1. Comparison of our results with those reported in 2014 in Morocco [12].

|                               | Majida H’ serie | Our serie |
|-------------------------------|-----------------|-----------|
|                               | ORb [95%]       | ORb       |
| Sex                           | 1.58 [0.5 - 4.6]| 2.01 [1.20 - 3.37] |
| Age                           | 3.19 [0.83 - 12.2]| 3.55 [2.09 - 6.04] |
| Diabetes                      | 3.8 [1.12 - 14.6]| 2.1 [1.22 - 3.62]  |
| Old re hospitalisation        | 8.5 [1.1 - 69.54]| 2.48 [1.47 - 4.18] |
| Time of hospitalisation       | 10.2 [3.36 - 30.6] | 15 [1.65 - 136.20] |
| Vein catheter                 | 2.08 [0.39 - 11.2]| 3.95 [1.39 - 11.24] |
| New surgery                   | 3.98 [1.4 - 11.25]| 2.23 [1.24 - 4.03]  |
| Antibiotic                    |                 | 4.08 [2.32 - 7.18]  |
| Imipenem                      | 17.5 [2.2 - 139.4]|          |
| Fluoroquinolones              | 6 [1.26 - 28.4]  |           |
| G3C                           | 13 [4.23 - 43.9] | MRB(Kp-BLSE) |
|                               |                 | MRB+      |

G3C: Third generation fluoroquinolones.

surveys. Epidemiological and clinical investigations: Before carrying out the investigations, the patients were informed about the study (theme, framework, advantages and objectives), the conditions of the examination and the sampling from an information sheet in order to obtain their informed consent. After obtaining their written and signed informed consent, patients were subjected to a standardized questionnaire to collect socio-demographic and clinical data. We conducted interviews in French (official language), Lingala (national language) according to the patient’s preference. A code and an identification number were assigned to each patient in order to guarantee data confidentiality and anonymity. Bacteriological investigation: The bacteriological investigation was carried out respecting the three phases of the biological examination: the pre-analytical, analytical and post-analytical phases. The pre-analytical phase, after having collected the clinical information of the patients, the bacteriological samples were taken according to the recommendations in force [7] [8] [9]. The analytical phase of the samples was carried out respecting the following steps: macroscopic examination, cytological examination, bacteriological examination, cultivation, identification of the species and carrying out antibiograms. During the statistical analysis, Excel version 2016 software was used for the compilation of the database, the construction of tables and graphs. And Epi Info software version 3.5.1 was used for the calculation of the rates and the comparison of the variables. For the qualitative variables we used frequencies; for the quantitative variables we used the mean and standard deviation or the median and quartiles when the standard deviation was greater than one tenth of the whole part of the mean. The extreme values were specified. Pearson’s chi-square test was used for the comparison of qualitative variables, when the conditions for its application were
not met the exact Fischer test was used. The t-Student test was used for comparison of means. Mann Whitney test was used for comparison of medians. The test was considered statistically significant if the p-value was less than 0.05. The raw odds ratio (ORb) with a 95% confidence interval was used to measure the association between carry at MRB and the explanatory variables. To do this, we performed a bivariate analysis between the dependent variable (sensitivity) with two modalities (MRB+ and MRB−) and the explanatory variables (independent variables or exposure variables) coded in binary mode. The adjusted odds ratio (ORA) with a 95% confidence interval was used to measure the specific effect of each risk factor in order to rule out confounding factors (confusions that exist between BMR infection and certain independent variables). Multivariate analysis by binomial logistic regression was used. For each given variable, when the odds ratio was greater than 1, then it multiplied the risk for a patient to be a carrier of BMR provided that his confidence interval does not contain the value 1 and that the p-value is lower to 0.05.

3. Results

There were 375 bacteriological samples from 258 patients. Among them 247 patients with 235 positive samples or 63%. The eleven (11) healthy patients. The median age was 33 with extremes ranging from 16 to 90. The female sex was predominant with a sex ratio of 0.6. The internal medicine, nephrology and hemodialysis departments had more patients in hospital, 16 out of 31, or 51.6%. The majority of MRB+ cases were found in internal medicine and nephrology with 12 cases (38.7%) and hemodialysis with 4 cases (12.9%) see Table 2. Urinary samples were in the majority with 74.5%. The germ *Escherichia coli* predominated in 30.3%. See Table 3. After the study of antibiotic susceptibility of species included 247, 113 and 134 were BMR+ a frequency of 45.7%. Methicillin-resistant *Staphylococcus aureus* (MRSA) was predominant (51.3%). Multivariate logistic regression analysis showed that the main risk factor was antibiotic use (ORA: 3.2 [1.9 - 5.4]; p-value < 0.01). Chronic renal failure and diabetes were not risk factors for carriage. The other risk factors identified were: hospitalization of more than 7 days (prolonged), *Staphylococcus aureus* infection and male sex. See Tables 4-7.

Table 2. Patients with a positive culture according to inpatient services.

| Impatients services     | POSITIVE CULTURE |
|-------------------------|------------------|
|                         | n | %  |
| Gynaecology obstetric  | 5 | 16.1|
| Pediatric               | 2 | 6.5 |
| Reanimation             | 8 | 25.8|
| Internal medicine       | 12| 38.7|
| Hemodialysis            | 4 | 12.9|
| All                     | 31| 100 |
Table 3. Species isolated according to the type of sample.

| Type of sample | species isolated | Urine n (%) | Vaginal secretion n (%) | Put n (%) | joint fluid n (%) | Hemodialysis catheter tip n (%) | Urinary catheter tip n (%) | Total n (%) |
|----------------|------------------|-------------|-------------------------|-----------|-----------------|-------------------------------|---------------------------|-------------|
| Urine          | *Escherichia coli* | 71 (79.8)   | 14 (15.7)               | 2 (2.2)   | 0 (0)           | 0 (0)                         | 2 (2.3)                   | 89 (100)    |
|                | *Klebsiella pneumoniae* | 21 (65.6)   | 6 (18.8)                | 5 (15.6)  | 0 (0)           | 0 (0)                         | 0 (0)                     | 32 (100)    |
|                | *Enterobacter cloacae* | 11 (91.7)   | 0 (0)                   | 1 (8.3)   | 0 (0)           | 0 (0)                         | 0 (0)                     | 12 (100)    |
|                | *Citrobacter freundii* | 3 (100)     | 0 (0)                   | 0 (0)     | 0 (0)           | 0 (0)                         | 0 (0)                     | 3 (100)     |
|                | *Proteus mirabilis* | 6 (75)       | 0 (0)                   | 2 (25)    | 0 (0)           | 0 (0)                         | 0 (0)                     | 8 (100)     |
|                | *Pseudomonas aeruginosa* | 16 (69.6)   | 5 (21.7)                | 0 (0)     | 0 (0)           | 0 (0)                         | 0 (0)                     | 23 (100)    |
|                | *Citrobacter freundii* | 3 (100)     | 0 (0)                   | 0 (0)     | 0 (0)           | 0 (0)                         | 0 (0)                     | 3 (100)     |
|                | *Proteus mirabilis* | 6 (75)       | 0 (0)                   | 2 (25)    | 0 (0)           | 0 (0)                         | 0 (0)                     | 8 (100)     |
|                | *Staphylococcus aureus* | 66 (82.5)   | 4 (5)                   | 4 (5)     | 2 (2.5)         | 4 (5)                         | 0 (0)                     | 80 (100)    |
|                | *Staphylococcus saprophiticus* | 30 (71.4)   | 12 (28.6)               | 0 (0)     | 0 (0)           | 0 (0)                         | 0 (0)                     | 12 (100)    |

Total 224 (76.2) 41 (13.9) 21 (7.1) 2 (0.7) 4 (1.4) 2 (0.7) 294 (100)

Table 4. Bivariate analysis of risk factors for MRB carriage.

| Total N = 247 | Sensibility MRB+ n = 113 | Sensibility MRB– n = 134 | rOR (CI 95%) | p-value |
|---------------|--------------------------|--------------------------|---------------|---------|
| n (%)         | n (%)                    | n (%)                    |               |         |
| Age in years  |                          |                          |               |         |
| ≥40           | 80 (32.4)                | 54 (47.8)                | 26 (19.4)     | <0.0001’|
| ≤40           | 167 (67.6)               | 59 (52.2)                | 108 (80.6)    |         |
| Sex           |                          |                          |               |         |
| Male          | 102 (41.3)               | 57 (50.4)                | 45 (33.6)     | 0.0094’ |
| Feminine      | 145 (58.7)               | 56 (49.6)                | 89 (66.4)     |         |
| Professional activity |                  |                          |               |         |
| No renumerating | 179 (72.5)               | 95 (84.1)                | 84 (62.7)     | 0.0002’ |
| Renumerating activity | 68 (27.5)               | 18 (15.9)                | 50 (37.3)     |         |
| Educational level |                      |                          |               |         |
| Schooled      | 72 (29.1)                | 44 (28.9)                | 28 (20.9)     | 0.02’   |
| No schooled   | 175 (70.9)               | 69 (61.1)                | 106 (79.1)    |         |
| Origin        |                          |                          |               |         |
| Inpatient     | 36 (14.6)                | 25 (22.1)                | 11 (8.2)      | 0.003’  |
| Outpatient    | 211 (85.4)               | 88 (77.9)                | 123 (91.8)    |         |
| Hospital stay |                          |                          |               |         |
| ≥7            | 20 (55.6)                | 15 (60.0)                | 1 (9.1)       | 0.009’  |
| ≤7            | 16 (44.4)                | 10 (40.0)                | 10 (90.9)     |         |
| Hospitalization during the year |            |                          |               |         |
| Yes           | 98 (39.7)                | 58 (51.3)                | 40 (29.9)     | 2.5 (1.5 - 4.2) | 0.0007’ |
| No            | 149 (60.3)               | 55 (48.7)                | 94 (70.1)     |         |

*significative p-value; rOR raw odds ratio; CI confidence interval.
### Table 5. Bivariate analysis of risk factors for MRB carriage.

|                          | Total | MRB+ | MRB− | rOR (CI 95%) | p-value |
|--------------------------|-------|------|------|--------------|---------|
|                          | n (%) | n (%)| n (%)|              |         |
| **Surgery in 30 days**  | 2.2 (1.2 - 4) | 0.008’ |       |              |         |
| Yes                      | 61 (24.7) | 37 (32.7) | 24 (17.9) |              |         |
| No                       | 186 (75.3) | 76 (67.3) | 110 (82.1) |              |         |
| **Diabetes**             | 2.1 (1.2 - 3.6) | 0.009’ |       |              |         |
| Yes                      | 79 (32.0) | 46 (40.7) | 33 (24.6) |              |         |
| No                       | 168 (68.0) | 67 (59.29) | 101 (75.4) |              |         |
| **Antibiotic in 30 days**| 4.1 (2.3 - 7.2) | <0.0001’ |       |              |         |
| Yes                      | 82 (33.2) | 56 (49.6) | 26 (19.4) |              |         |
| No                       | 165 (66.8) | 57 (50.4) | 108 (80.6) |              |         |
| **Injectable treatment** | 3.95 (1.4 - 11.2) | 0.009’ |       |              |         |
| Yes                      | 20 (8.1) | 14 (12.4) | 5 (3.7) |              |         |
| No                       | 227 (91.9) | 99 (87.6) | 129 (96.3) |              |         |
| **Indwelling surgery**  | 3.0 (1.1 - 8.1) | 0.03’ |       |              |         |
| Yes                      | 20 (8.1) | 14 (12.4) | 6 (4.5) |              |         |
| No                       | 227 (91.9) | 99 (87.6) | 128 (95.5) |              |         |
| **Species (pseudomonas aeruginosa)** | 1.1 (0.5 - 2.6) | 0.83 |       |              |         |
| Yes                      | 23 (9.3) | 11 (9.7) | 12 (9.0) |              |         |
| No                       | 224 (90.9) | 102 (90.3) | 122 (91.0) |              |         |
| **Species (staphylococcus aureus)** | 5.4 (3.0 - 9.7) | 0.0001’ |       |              |         |
| Yes                      | 80 (32.4) | 58 (51.3) | 22 (16.4) |              |         |
| No                       | 167 (67.6) | 55 (48.7) | 112 (83.6) |              |         |

*p significative p-value; rOR raw odds ratio; CI confidence interval.

### Table 6. Logistic regression of MRB risk factors.

|                          | Total | MRB+ | MRB− | aOR (CI 95%) | p-value |
|--------------------------|-------|------|------|--------------|---------|
|                          | n (%) | n (%)| n (%)|              |         |
| **Age in years**        | 0.25  |      |      |              |         |
| ≥40                      | 80 (32.4) | 54 (47.8) | 26 (19.4) | 1^ |         |
| ≤40                      | 167 (67.6) | 59 (52.2) | 108 (80.6) | 1.8 (0.6 - 5.9) |         |
| **Sex**                 | 0.001’ |      |      |              |         |
| Male                     | 102 (41.3) | 57 (50.4) | 45 (33.6) | 1^ |         |
| Feminine                 | 145 (58.7) | 56 (49.6) | 89 (66.4) | 2.8 (1.5 - 5.1) |         |
| **Professional activity**| 0.26  |      |      |              |         |
| No renumerating          | 179 (72.5) | 95 (84.1) | 84 (62.7) | 1^ |         |
Continued

| Renumerating activity | Total | MRB+  | MRB−  | aOR (CI 95%) | p-value |
|------------------------|-------|-------|-------|--------------|---------|
| 68 (27.5)              | 18 (15.9) | 50 (37.3) | 0.3 (0.05 - 2.22) |        |

| Educational level | 0.60 |
|-------------------|------|
| Schooled 72 (29.1) | 44 (28.9) | 28 (20.9) | 1^ |
| No schooled 175 (70.9) | 69 (61.1) | 106 (79.1) | 1.3 (0.6 - 2.5) |

| Origin | 0.0004* |
|--------|--------|
| Inpatient 36 (14.6) | 25 (22.1) | 11 (8.2) | 1^ |
| Outpatient 211 (85.4) | 88 (77.9) | 123 (91.8) | 5.71 (2.2 - 15.1) |

| Hospital stay | <0.0001* |
|---------------|----------|
| ≥7 20 (55.6) | 15 (60.0) | 1 (9.1) | 1^ |
| ≤7 16 (44.4) | 10 (40.0) | 10 (90.9) | 18.1 (9.6 - 31.1) |

| Hospitalization during the year | 0.07 |
|---------------------------------|------|
| Yes 98 (39.7) | 58 (51.3) | 40 (29.9) | 1^ |
| No 149 (60.3) | 55 (48.7) | 94 (70.1) | 2.2 (0.9 - 4.1) |

*significative p-value; ^aOR ajusted odds ratio; CI confidence interval.

Table 7. Logistic regression of MRB risk factors.

| Total | MRB+  | MRB−  | aOR (CI 95%) | p-value |
|-------|-------|-------|--------------|---------|
| n (%) | n (%) | n (%) |              |         |

| Surgery in 30 days | 0.75 |
|--------------------|------|
| yes 61 (24.7) | 37 (32.7) | 24 (17.9) | 1^ |
| No 186 (75.3) | 76 (67.3) | 110 (82.1) | 1.4 (0.2 - 11.3) |

| Diabetis | 0.06 |
|----------|------|
| yes 79 (32.0) | 46 (40.7) | 33 (24.6) | 1^ |
| No 168 (68.0) | 67 (59.29) | 101 (75.4) | 1.7 (0.9 - 2.9) |

| Antibiotic in 30 days | <0.001* |
|-----------------------|---------|
| yes 82 (33.2) | 56 (49.6) | 26 (19.4) | 1^ |
| No 165 (66.8) | 57 (50.4) | 108 (80.6) | 3.2 (1.9 - 5.4) |

| Injectable treatment | 0.50 |
|----------------------|------|
| yes 20 (8.1) | 14 (12.4) | 5 (3.7) | 1^ |
| No 227 (91.9) | 99 (87.6) | 129 (96.3) | 1.3 (0.7 - 2.5) |

| Indwelling surgery | 0.62 |
|--------------------|------|
| yes 20 (8.1) | 14 (12.4) | 6 (4.5) | 1^ |
| No 227 (91.9) | 99 (87.6) | 128 (95.5) | 1.3 (0.6 - 2.5) |

| Spacies (staphylococcus aureus) | 0.02* |
|---------------------------------|------|
| Yes 80 (32.4) | 58 (51.3) | 22 (16.4) | 1^ |
| No 167 (67.6) | 55 (48.7) | 112 (83.6) | 5.9 (1.3 - 26.3) |

*significative p-value; ^aOR ajusted odds ratio; CI confidence interval.
4. Discussion

The different stages from the sampling to the post analytical were respected according to the standards and recommendations in force [12]-[17].

In this study, the frequency of multidrug resistance bacteria (MRB) was 45.7%. In the majority of cases these were MRSA (51.3%), EBRC3G (38.9%) and PAMR (9.7%). We have not isolated strains of *Acinetobacter baumannii*. In France, Pierrot S had returned 28.5% in 2015 [18] while in Morocco, Azmoun S had brought back 25.5% to the CHU of MARRAKECH in 2016 [17] and Saadaoui M in 2008 had found 19% to the Hassan II hospital in Settet [14]. Several reasons can explain these results.

Male sex was statistically associated with antibiotic resistance as reported by Pierrot S, in 2015 in France [18], Birgand G and al in 2013 in France [19], MBOYO F and al in 2016 in Morocco [9], then Koujane L in 2011 in Morocco [16]. The involvement of the male sex in the occurrence of BMR is not clearly established despite the unanimity of several authors [10] [15] [18] [20]. In the present study, a statistically significant association was found between hospitalization and BMR carriage. These results were also reported by MBOYO F. *et al.* 2016 in Morocco [9] and Deguenevo L *et al.* in Senegal [10]. Normal (sensitive) flora can be replaced by resistant flora (hospital strains) during hospitalization. Invasive manipulations increase the risk of developing MRB [18] [19]. It is thus that in this series patients were treated by injection and had an indwelling catheter.

The impact of the consumption of antibiotics on the occurrence of resistance has been documented [21] [22] [23]. Antibiotics do not induce resistance in themselves, but they lead to the selection of resistant mutants by reducing or even destroying the patient’s sensitive normal flora, thus allowing resistant bacteria to proliferate [23]. These MRBs acquired during hospitalization can persist for several months or even years [24]-[31]. This explains the predominance of MRB in our series in patients with a history of hospitalization within the year, surgery within 30 days and antibiotics taken within 30 days. The existence of an underlying pathology such as chronic renal failure, diabetes mellitus; recurrent urinary tract infections and HIV infection in the acquisition of BMRs had been reported by several authors [32] [33] [34]. In our series, diabetes mellitus was statistically associated with a risk of MRB as in the work of Majida H and al in 2014 [12]. Recurrent urinary tract infections, chronic renal failure and HIV have not been statistically associated with risk factors for the occurrence of resistance to MRB as has been proven in other studies [12] [35] [36]. This can be explained by the small size of our sample.

5. Conclusion

Probabilistic antibiotic therapy leads to the selection of MRBs. Visits to hospital patients by community populations lead to the dissemination of these MRBs, first of all SARMs, to the community. Kidney failure is not a risk factor for bac-
aterial resistance. Short hospitalizations and the rational use of antibiotics are effective means of combating this phenomenon.

Confidentiality and anonymity

The study was carried out with respect for patient anonymity and the confidentiality of information.

Conflicts of Interest

The authors or anyone who participated in this study declare no conflict of interest.

References

[1] Carle, S. (2009) La résistance aux antibiotiques: Un enjeu de santé publique important. Pharmacological Reviews, 42, 120-125.

[2] Woodford, N., Turton, J.F. and Livermore, D.M. (2011) Multiresistant Gram-Negative Bacteria: The Role of High-Risk Clones in the Dissemination of Antibiotic Resistance. Microbiology and Molecular Biology Reviews, 35, 736-755. https://doi.org/10.1111/j.1574-6976.2011.00268.x

[3] Bertrand, X., Costa, Y. and Pina, P. (2005) Surveillance de la résistance bactérienne aux antibiotiques dans les bactériémies: Données de l’observatoire national de l’épidémiologie de la résistance bactérienne aux antibiotiques (ONERBA) 1998-2003. Medicine Tropicale, 35, 329.

[4] Trystram, D., Chardon, H., Péan, Y., Delarbre, J., Costa, Y., Maugat, S., et al. (2012) Réseau européen de surveillance de la résistance bactérienne aux antibiotiques (EARS): Résultats 2001-2010 pour la France et place en Europe. Epidemiologisches Bulletin, LV N° 317, 42-43.

[5] MacGowan, A. and Macnaughton, E. (2017) Antibiotic Resistance. Medicine Tropicale, 45, 622-628. https://doi.org/10.1016/j.mpmed.2017.07.006

[6] Brun-Buisson, C. (2015) Le dépistage des porteurs de bactéries multirésistantes: Chez quels patients? Annales Françaises d’Anesthésie et de Réanimation, 24, 304-314. https://doi.org/10.1007/s13546-014-0940-7

[7] Gérôme, P., Dusseau, J.-Y., Masseron, T. and Bercion, R. (2001) La phase pré-analytique en bactériologie. FEMS Microbiology Reviews, 200, 23-30. https://doi.org/10.1016/S0338-9988(01)80227-4

[8] World Health Organization (2018) Global Antimicrobial Resistance Surveillance System (GLASS) Report: Early Implementation 2017-2018. European Center for Disease Prevention and Control, Stockholm, 1-108.

[9] Mboyo, F.C. (2016) Incidence, facteurs de risque et épidémiologie des bactéries multirésistantes en milieux de réanimation: Étude prospective de six mois à l’HMIMV-Rabat 2016. These de Médecine. Université MOHAMMED V, 140 p.

[10] Déguénonvo, L.F., Traoré, K., Badiane, N.D., Ka, R., Cissoko, Y., Diouf, A., et al. (2016) Résultats d’une enquête d’incidence des cas d’infections nosocomiales à bactéries multirésistantes dans un centre hospitalier à Dakar (Sénégal). Revue Malienne d’Infectiologie et de Microbiologie, 13, 120-127.

[11] Rachel, M., Gabriel, A., Etienne, N., Esther, O.N., Fabien, N.R., Claudette, Y.G., et al. (2014) Activity of Bêta-Lactam Antibiotics and Production of Beta-Lactamases in Bacteria Isolated from Wound Infections in Brazzaville, Congo. African Journal of
Majida, H. (2014) Les facteurs de risque des infections à BMR au niveau des services de réanimation, CHU Ibn Rochd, Casablanca. Mémoire de Master d’Épidémiologie de Santé Publique. Ecole Nationale de Santé Publique du Royaume de Maroc, 130 p.

Aissaoui, Y., Chouaib, N., Chouikh, C., Rafai, M., Azendour, H., Balkhi, H., et al. (2010) Bactériémies liées aux cathéters veineux centraux: Étude prospective dans une unité de réanimation médicale marocaine. Annales Françaises d’Anesthésie et de Réanimation, 50, 7-9. https://doi.org/10.1016/j.annfar.2010.09.011

Saadaoui, M. (2008) La fréquence des bactéries multirésistantes à l’hôpital Hassan II de Settat en 2008. These de pharmacie université Mohamed V, rabat, 121 p.

Laudat, P., Galinier, J.L., Cattoen, C., Ferroni, A., Lamy, B., Courcol, R., et al. (2014) L’accréditation en bactériologie: Enjeux, difficultés et particularités. FEMS Microbiology Reviews, 204, 2530. https://doi.org/10.1016/S1773-035X(14)72442-6

Koujane, L. (2011) Epidemiologie et résistance des BMR à l’hôpital d’instruction Mohamed V de rabat 2011. http://ao.um5s.ac.ma/xmlui/handle/123456789/1851

Azmoun, S. (2016) Epidemiologie de la résistance bactérienne aux antibiotiques au CHU de MARRAKECH. These de medicine, Faculté de médecine et e pharmacie de MARRAKECH, 117 p.

Pierrot, S. (2015) Portage de bactéries multirésistantes en structures d’accueil pour personnes âgées: Évaluation d’une politique de dépistage cible en fonction des facteurs de risque. Thèse de Pharmacie, Université de Lorraine, Lorraine, 110 p.

Birgand, G. and Lucet, J.C. (2013) Politique de dépistage des BMR: Quand et qui faut-il dépister? Revue Francaise des Laboratoires, 453, 29-39. https://doi.org/10.1016/S1773-035X(13)72079-3

Djuric, O., Jovanovic, S., Stosovic, B., Tosic, T., Jovanovic, M. and Markovic-Denic, L. (2016) Antimicrobial Resistance of Selected Invasive Bacteria in a Tertiary Care Center: Results of a Prospective Surveillance Study. Journal of Infection, 10, 1325-1331. https://doi.org/10.3855/jidc.7695

Ouedraogo, A.S., Somé, D.A., Dakouré, P.W.H., Sanon, B.G., Birba, E., Poda, G.E.A., et al. (2011) Profil bactériologique des infections du site opératoire au centre hospitalier universitaire Soro Sanou de Bobo Dioulasso. Medicine Tropicale, 71, 49-52.

Rakotovao-Ravahatra, Z.D., Randriatsarafara, F.M., Rasoanandrasana, S., Ravero-hanta, L. and Rakotovao, A.L. (2017) Phénotypes de résistance des souches d’Escherichia coli responsables d’infection urinaire au laboratoire du Centre Hospitalo-Universitaire de Befelatanana Antananarivo. The Pan African Medical Journal, 26, 5-9. https://doi.org/10.11604/pamj.2017.26.166.11828

Monnet, D. (2014) Consommation d’antibiotiques et résistance bactérienne. Annales Françaises d’Anesthésie et de Réanimation, 60, 13-17.

Rabaud, C. (2013) Réflexion sur les mesures pratiques qui doivent être envisagées pour préserver ce bien inestimable que sont les antibiotiques et lutter contre l’extension progressive des résistances bactériennes. Tropical Medicine and Infectious Disease, 43, 97-99. https://doi.org/10.1016/j.medmal.2013.02.012

Ruppé, É. and Andremont, A. (2013) Le microbiote intestinal est l’avenir de la multirésistance bactérienne. The Journal of Antibiotics, 15, 166-177. https://doi.org/10.1016/j.antinf.2013.08.002

Cattoen, C. (2015) Persistance du portage de bactéries multirésistantes après la réanimation. Annales Françaises d’Anesthésie et de Réanimation, 24, 249-255.
[27] Haverkate, M., Derde, L. and Brun-Buisson, C. (2014) Duration of Colonization with Antimicrobial-Resistant Bacteria after ICU Discharge. *Intensive Care Medicine*, 40, 564-571. [https://doi.org/10.1007/s00134-014-3225-8](https://doi.org/10.1007/s00134-014-3225-8)

[28] Apisarnthanarak, A., Bailey, T. and Fraser, V. (2009) Duration of Stool Colonization in Patients Infected with Extended-Spectrum β-Lactamase Producing *Escherichia coli* and *Klebsiella pneumoniae*. *Clinical Infectious Diseases*, 46, 1322-1323. [https://doi.org/10.1086/533475](https://doi.org/10.1086/533475)

[29] O’Fallon, E., Gautam, S. and D’Agata, E. (2009) Colonization with Multidrug-Resistant Bacteria: Prolonged Duration and Frequent Cocolonization. *Clinical Infectious Diseases*, 48, 1375-1381. [https://doi.org/10.1086/598194](https://doi.org/10.1086/598194)

[30] Mattner, F., Bieritz, F. and Ziesing, S. (2010) Long-Term Persistence of MRSA in Readmitted Patients. *Infection*, 38, 363-371. [https://doi.org/10.1007/s15010-010-0038-8](https://doi.org/10.1007/s15010-010-0038-8)

[31] Robisek, A., Beaumont, J. and Peterson, L. (2009) Duration of Colonization with Methicillin-Resistant *Staphylococcus aureus*. *Clinical Infectious Diseases*, 48, 910-913. [https://doi.org/10.1086/597296](https://doi.org/10.1086/597296)

[32] Scanvic, A., Denic, L., Gaillon, S. and Giry, P. (2010) Duration of Colonization by Methicillin-Resistant *Staphylococcus aureus* after Hospital Discharge and Risk Factors for Prolonged Carriage. *Clinical Infectious Diseases*, 32, 1393-1398. [https://doi.org/10.1086/320151](https://doi.org/10.1086/320151)

[33] Larsson, A.K., Gustafsson, E. and Nilsson, A.C. (2011) Duration of Methicillin-Resistant *Staphylococcus aureus* Colonization after Diagnosis: A Four-Year Experience from Southern Sweden. *Scandinavian Journal of Infectious Diseases*, 43, 456-462. [https://doi.org/10.3109/00365548.2011.562530](https://doi.org/10.3109/00365548.2011.562530)

[34] Marmouch, H., Aouam, A., Toumi, A., Loussaief, C. and Chakroun, M. (2014) P116 Diabète et bactéries multirésistantes: Analyse de 95 cas. *Diabetes & Metabolism*, 40, 57. [https://doi.org/10.1016/S1262-3636(14)72408-5](https://doi.org/10.1016/S1262-3636(14)72408-5)

[35] Estournet, C. (2013) Acquisition d’entérobactéries productrices de bétalactamases à spectre élargi au cours des trois premiers mois de transplantation rénale: Étude épidémiologique et impact clinique. *Nephrology*, 10, 3-8.

[36] Ayzac, L., Bisaccia, V., Chatellet, C., Darre-Plat, S., Gardes, S., Garcia, E.L., et al. (2017) Protocole du réseau de surveillance des infections en hémodialyse. *Journal of Nephrology*, 87, 62-64.